ANDA 62525, held by Quantum Pharmics. Nystatin.
As of Nov 14, 2026, ANDA 62525 (Nystatin), held by Quantum Pharmics, was not approved, with 0 approved supplements and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| Nystatin500,000 UNITS ยท tablet;oral | Nystatin | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
